[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356803-105":59,"doc-detail-356803-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluation-of-talimogene-laherparepvec-for-the-treatment-of-advanced-nonmelanoma-skin-cancers-original-article","Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers - Original Article","","Talimogene laherparepvec (T-VEC) is an intralesional, injectable oncolytic herpes virus with FDA approval for Stage III–IV melanoma. Its role in nonmelanoma skin cancers (NMSC) such as Merkel cell carcinoma (MCC) and squamous cell carcinoma (SCC), including when combined with concurrent immune therapy, is not well established. This retrospective single-institution study evaluates outcomes of T-VEC in MCC and SCC from May 2016 to May 2023.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-talimogene-laherparepvec-for-the-treatment-of-advanced-nonmelanoma-skin-cancers-original-article/356803/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-talimogene-laherparepvec-for-the-treatment-of-advanced-nonmelanoma-skin-cancers-original-article/356803.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is Talimogene laherparepvec (T-VEC) and why was it studied for NMSC?","Question",{"text":112,"@type":113},"T-VEC is an intralesional oncolytic herpes virus. The study evaluates its outcomes in MCC and SCC, where its utility and benefit with concurrent immune therapy are poorly defined.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted and who were the patients?",{"text":117,"@type":113},"This retrospective single-institution cohort included adults with advanced or refractory MCC or SCC treated with T-VEC from May 2016 to May 2023 at the University of Alabama at Birmingham.",{"name":119,"@type":110,"acceptedAnswer":120},"What tumor response outcomes were reported for MCC and SCC?",{"text":121,"@type":113},"Ten MCC and three SCC patients were eligible. Overall, six achieved complete response (CR), one partial response (PR), and six progressive disease (PD). Of the CR group, two recurred at 8 and 56 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356803,1790181778,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","[https://doi.org/10.1245/s10434-026-19182-3](https://doi.org/10.1245/s10434-026-19182-3)  \nAnnals of Surgical Oncology (2026) 33:4985–4990  \nORIGINAL ARTICLE MELANOMA AND CUTANEOUS ONCOLOGY  \nEvaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers  \nJ. Slatton, BA1 · V. Jiminez, MD1 · J. Beam, BS1 · N. Rademacher, MD2 · K. Montgomery, MD, MSPH2 ·  \nS. Bateni, MD, MAS, MSW2,3 · K. Broman, MD, MPH2,3,4  \nReceived: 16 April 2025 / Accepted: 19 January 2026 / Published online: 22 February 2026 © The Author(s) 2026  \nAbstract  \nIntroduction Talimogene laherparepvec (T-VEC) is an intralesional, injectable oncolytic herpes virus that is FDA-approved to treat Stage III-IV melanoma. The utility of T-VEC for nonmelanoma skin cancers (NMSC), including Merkel cell carcinoma (MCC) and squamous cell carcinoma (SCC), as well as its use with concurrent immune therapy (IO), is poorly defined. The purpose of this study is to evaluate outcomes ofT-VEC for MCC and SCC with and without concurrent immune therapy. Methods This retrospective study included patients at a single institution with MCC or SCC and treated with T-VEC between May 2016 and May 2023. Abstracted cohort data were reported using descriptive statistics.  \nResults Ten MCC and three SCC patients were eligible. Four MCC patients and all three SCC patients received concurrent pembrolizumab. Overall, six patients achieved complete response (CR), one had partial response (PR), and six had progressive disease (PD) . Of the six patients who achieved CR, two recurred at 8 and 56 months. Those without recurrence had a durable response at a median follow-up of 25 months.  \nConclusions Our initial experience with a small, single-institution cohort demonstrated tumor response to intralesional T-VEC with or without immunotherapy in some patients with NMSC. Nearly 50% of participants had a complete response; two-thirds of responders remained relapse-free at the time of follow-up. Some observed responses are not attributable to T-VEC alone due to high usage rates of IO. Future work should expand to larger cohorts and focus on its use with and without immune therapy.  \nKeywords Oncolytic virus therapy · Talimogene laherparepvec · Non-melanoma skin cancer · Outcomes research · Retrospective cohort  \nNonmelanoma skin cancer (NMSC), including squamous cell, basal cell, and Merkel cell carcinoma, is an increasingly common problem in the United States. From 2005 to 2019, the incidence of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) increased from 402 to 787 per 100,000 persons.1 From 2000 to 2013, Merkel cell carcinoma (MCC)  \n* K. Broman, MD, MPH [kkbroman@mdanderson.org](kkbroman@mdanderson.org)  \n1 Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL  \n2 Department of Surgery, University of Alabama at Birmingham, Birmingham, AL  \n3 Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL  \n4 Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030  \nalso saw an increase in incidence from 0.5 to 0.7 per 100,000 persons.2 While most cases of NMSC present as localized disease amenable to surgical resection, some patients have advanced disease that cannot be cured by surgery.1 Treatment options are limited for these patients, who are often older, immune suppressed, and have additional comorbid conditions.  \nIntralesional therapies using oncolytic viruses represent one strategy for managing surgically unresectable cutaneous malignancies. Talimogene laherparepvec (T-VEC), a herpes simplex virus 1 (HSV-1)-based oncovirus, has demonstrated efficacy in treatment of Stage III and IV melanoma and received FDA approval for this indication in 2015.3 T-VECis a modified version of the JS17 strain of HSV-1 in which neurovirulence genes have been replaced by the human granulocyte-macrophage colony-stimulating factor (hGM-CSF) gene, which can instigate a","cbCaipQzTdpjxsA2","https://ap.wps.com/l/cbCaipQzTdpjxsA2","pdf",515923,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is Talimogene laherparepvec (T-VEC) and why was it studied for NMSC?\",\"answer\":\"T-VEC is an intralesional oncolytic herpes virus. The study evaluates its outcomes in MCC and SCC, where its utility and benefit with concurrent immune therapy are poorly defined.\"},{\"question\":\"How was the study conducted and who were the patients?\",\"answer\":\"This retrospective single-institution cohort included adults with advanced or refractory MCC or SCC treated with T-VEC from May 2016 to May 2023 at the University of Alabama at Birmingham.\"},{\"question\":\"What tumor response outcomes were reported for MCC and SCC?\",\"answer\":\"Ten MCC and three SCC patients were eligible. Overall, six achieved complete response (CR), one partial response (PR), and six progressive disease (PD). Of the CR group, two recurred at 8 and 56 months.\"}]","Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers - Original Article | PDF",1790127352,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92e8309bd8d9804c1f8941275433b78d.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cb23aef4d6c31c96c25af173d094e09.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bd0102cebeda4bc91d93322c88faa33.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b30b6f69148cceff8fcf78182e32101e.webp",980,1301]